top of page
Gammatek ISPL LOGO

Gammatek ISPL

Gammatek ISPL

Gammatek_green_LOGO_FINAL.png

A ‘shakeout’ in early-stage AI may be coming as VC money gets pickier on valuations

Writer: Gammatek ISPL
Gammatek ISPL
Sep 4
5 min read

By Gammatek ISPL, Industrial Systems & Compliance Analyst at Gammatek ISPL Published September 2026 | 11 min read

This analysis draws on public venture capital data (PitchBook, CRV, Crunchbase-sourced figures) current as of September 2026, combined with Gammatek's own experience evaluating and integrating third-party AI and software vendors for industrial clients. This is independent commentary — Gammatek has no financial relationship with the investors or companies named below.

Why This Matters to You, Not Just to Silicon Valley

If your plant has signed up for an AI-powered monitoring tool, a predictive maintenance platform, or a "smart" compliance assistant in the last two years, this story affects you more directly than it looks. Venture capitalists are signaling that a chunk of the AI startups currently selling into manufacturing, chemical, and pharma companies may not survive the next 12 months in their current form — and if your vendor is one of them, you could be left holding a contract, an integration, and a pile of plant data with nowhere to go.

That's the real stakes behind what sounds like a Wall Street story. This isn't abstract market commentary — it's a vendor-risk question for anyone who has bought, or is about to buy, AI software for industrial operations.


Chart showing concentration of AI venture funding into mega-rounds versus early-stage startups, 2026
Venture money is flowing to a small number of giant AI companies — leaving a widening gap for smaller AI vendors serving specific industries.

What's Actually Happening

The headline event: a "shakeout" in early-stage AI is being predicted by venture investors, driven by valuations in parts of the market that have started to look stretched relative to the underlying business fundamentals. Jakub Nytra, founding partner at venture firm Purple Ventures, put it plainly: investors are becoming far more demanding about distinguishing genuine technology value from what is, in his words, a feature dressed up as a business, and he expects capital to get noticeably more selective over the next six to twelve months.


That caution sits alongside numbers that look enormous on the surface. Global AI venture investment hit roughly $289–300 billion in the first quarter of 2026 alone — already surpassing all of 2025's total AI funding in a single quarter. But the composition of that number is the real story: the overwhelming majority of it went to a handful of frontier AI labs. OpenAI alone closed a $122 billion round in Q1 2026, and Anthropic raised $30 billion in the same period. Those two rounds together account for a huge share of the quarter's entire AI funding total.

Meanwhile, at the earlier stages — seed and Series A, where most of the specialized, industry-specific AI tools (the kind actually being pitched to manufacturing and industrial buyers) tend to sit — the picture is tighter. Data from CRV shows the median time between a seed round closing and a Series A closing has stretched to around 20 months, meaning many founders who planned their runway around a 12-month path to their next raise are now facing a real cash gap. PitchBook's Q2 2026 valuation data shows a similar bifurcation: AI companies overall saw stronger valuation step-ups than non-AI companies, but that premium becomes dramatically more concentrated at Series D and later — largely reflecting a small number of already-dominant companies, not the broader field of smaller AI vendors.


Mega-rounds (frontier AI labs)

Early-stage (seed / Series A)

Funding availability

Abundant, record-breaking

Selective, criteria-driven

Typical buyer relevance

Rarely sold directly to industrial plants

Often the exact category selling to manufacturers (monitoring, compliance, maintenance AI)

Time to next round

Not applicable — many are near-IPO scale

Stretched to ~20 months seed-to-Series A

Investor scrutiny

High absolute dollars, thesis-driven

Increasing scrutiny on real revenue, retention, margins

Why Vendor Selection Just Got Riskier for Industrial Buyers

Here's the part that matters most if you're the one signing a contract with an AI vendor for your plant: a startup that raised a comfortable seed round in 2023 or 2024, riding general AI enthusiasm, is now facing investors who want to see real retention, real margins, and a real moat before writing the next check. Not every vendor will get there.

For a manufacturing or pharma buyer, that translates into a few concrete risks:

  • Vendor continuity risk. If a startup's next funding round falls through, you may be left mid-integration with a tool that stops receiving updates, support, or security patches.

  • Data portability risk. Plant sensor data, maintenance logs, and compliance records fed into a shut-down vendor's platform may become difficult or impossible to retrieve cleanly.

  • Compliance continuity risk. For regulated industries (pharma, chemical), a vendor disappearing mid-audit-cycle can create real regulatory exposure if your documentation trail depends on their platform staying operational.

This isn't a reason to avoid AI vendors — it's a reason to evaluate them differently than you'd evaluate an established enterprise software provider.

A Practical Framework for Evaluating AI Vendors Right Now

Based on Gammatek's own vendor evaluations for clients integrating third-party tools into compliance and operations workflows, a few questions are worth asking before signing with any early-stage AI vendor in this environment:

  1. What funding stage are they at, and when did they last raise? A startup that raised its seed round more than 18-20 months ago without a follow-on is statistically in a harder spot right now, per the CRV data above.

  2. Do they have paying customers beyond pilot programs? Investors are now weighing revenue quality heavily — genuine adoption, not just logo counts, is what keeps a vendor fundable.

  3. What happens to your data if they shut down or get acquired? Get this in writing — data export rights and format should be a contract term, not an assumption.

  4. Is their product a full solution or a thin AI feature wrapped around someone else's infrastructure? Nytra's "feature dressed up as a business" framing is a useful filter — ask what happens to the product if the underlying foundation model API pricing changes.

  5. Do they have a credible path to profitability, or are they dependent on continuous fundraising to operate? For mission-critical plant systems, this matters more than flashy demos.

None of this means avoiding smaller AI vendors — some of the most useful, purpose-built industrial AI tools come from exactly this stage of company. It means building contractual and operational safeguards assuming any given vendor might not survive the next funding cycle, and reserving your most safety-critical, compliance-sensitive workflows for platforms with demonstrated financial stability.

The Bigger Picture: A Bifurcating Market, Not a Collapsing One

It's worth being precise about what this "shakeout" actually is and isn't. This isn't a prediction that AI as a category is collapsing — corporate investors alone accounted for a record 87.9% of US AI venture deal value in 2026, and acquisition activity in the space has reached a decade-high total value. Capital is still moving into AI in enormous volume. What's changing is the distribution: money is concentrating hard into a small number of proven, large-scale players, while the long tail of smaller, more speculative AI startups faces a genuinely tougher road to their next check.

For industrial buyers, the practical takeaway isn't "avoid AI vendors" — it's "diversify your risk assessment the way you would for any critical supplier." The same diligence you'd apply to an equipment supplier's financial stability now needs to extend to your software vendors, especially ones built on the current AI funding wave.

Where This Fits Into Your Broader Vendor Risk Strategy

Evaluating vendor financial stability is really just one more input into the same compliance and risk-management discipline manufacturing and pharma plants already apply to physical suppliers, equipment, and safety systems — it's the same muscle, applied to a newer category of vendor.

 
 
 

Comments

bottom of page